Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00279019 |
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK233705 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary disease.
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK233705 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary disease.
Condition | Intervention | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: GSK233705 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Safety Study |
Official Title: | A Randomised, Double Blind, Placebo-Controlled, Double Dummy, 4-Way Cross-Over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Inhaled Doses of GSK233705 and Tiotropium Bromide (18µg) Via DPI in COPD Patients |
Estimated Enrollment: | 32 |
Study Start Date: | December 2005 |
Ages Eligible for Study: | 40 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Germany | |
GSK Investigational Site | |
Berlin, Germany, 14050 | |
Germany, Niedersachsen | |
GSK Investigational Site | |
Hannover, Niedersachsen, Germany, 30625 | |
Germany, Schleswig-Holstein | |
GSK Investigational Site | |
Grosshansdorf, Schleswig-Holstein, Germany, 22927 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | AC2103473 |
Study First Received: | January 17, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00279019 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
COPD GSK233705 |
Naphazoline Oxymetazoline Lung Diseases, Obstructive Respiratory Tract Diseases Bromides Guaifenesin |
Phenylephrine Lung Diseases Respiration Disorders Phenylpropanolamine Tiotropium Pulmonary Disease, Chronic Obstructive |